Standard Biotools (LAB) Receivables - Other (2021)

Standard Biotools' (LAB) quarterly Receivables - Other came in at $2.1 million in Q2 2021, down 25.0% on a QoQ basis from $2.8 million in Q1 2021.

Standard Biotools (LAB) Receivables - Other (2021) Analysis & Trends

Standard Biotools (LAB) has 1 years of Receivables - Other data on file, last reported at $2.1 million in Q2 2021.

On a quarterly basis, Receivables - Other changed N/A year-over-year to $2.1 million in Q2 2021; TTM through Jun 2021 was $2.1 million, a N/A change from a year earlier, with the FY2021 full-year figure at $2.8 million, changed N/A from the prior year.
Receivables - Other for Q2 2021 stood at $2.1 million, down from $2.8 million in the prior quarter.
Over the last five years, Receivables - Other for LAB reached as high as $2.8 million in Q1 2021 and fell as low as $2.1 million in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.67 Bn	176.38 Bn	6.27 Bn
2	Stryker	128.91 Bn	126.03 Bn	3.81 Bn
3	Medtronic	108.84 Bn	99.62 Bn	6.41 Bn
4	Boston Scientific	68.57 Bn	67.12 Bn	3.61 Bn
5	Edwards Lifesciences	48.68 Bn	45.01 Bn	1.29 Bn
6	Dexcom	28.42 Bn	27.31 Bn	750.30 Mn
7	GE HealthCare Technologies	28.38 Bn	26.09 Bn	1.98 Bn
8	Smith & Nephew	26.94 Bn	26.36 Bn	-
9	Koninklijke Philips	25.50 Bn	22.38 Bn	2.07 Bn
10	Standard Biotools	309.82 Mn	-145.35 Mn	11.31 Mn

Download Data